10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

Anti-IL-27Ralpha Reference Antibody (Synthekine patent anti-IL-27Ralpha)

Catalog # APR11368

Product Information

Application	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	Q6UWB1
Reactivity	Human
Clonality	Monoclonal
Isotype	IgG1-CS
Calculated MW	69474


Additional Information

Target/Specificity	IL-27Ralpha
Expression system	CHO


Protein Information

Name	IL27RA (HGNC:17290)
Synonyms	CRL1, TCCR, WSX1
Function	Signal-transducing subunit for an heterodimeric cytokine composed of IL27/p28 and a soluble receptor EBI3 (PubMed:14764690, PubMed:36930708). Heterodimerizes with IL6ST/GP130 to mediate signal transduction in response to the heterodimeric cytokine IL27/p28-EBI3. This signaling system acts through STAT3 and STAT1 (PubMed:14764690, PubMed:38509369). Also acts as a signaling receptor as part of the humanin receptor complex; binding of MT-RNR2/humanin (HN) activates the intracellular JAK-STAT3 signaling pathway leading to neuroprotection (PubMed:19386761). Involved in the regulation of Th1-type immune responses (By similarity). Also appears to be involved in innate defense mechanisms (PubMed:14764690).
Cellular Location	Membrane; Single-pass type I membrane protein.
Tissue Location	Highly expressed in lymphoid tissues such as spleen, lymph nodes and peripheral blood leukocytes. Weakly expressed in other tissues examined including heart, brain, fetal and adult lung, liver, skeletal muscle, kidney, pancreas, prostate, testis, ovary, small intestine, kidney and colon. In the lymphoid system, higher level expression in CD4+ T-cell subsets than in CD8+ T-cell subsets. Also weaker expression in CD19+ B-cells and monocytes


Images



Anti-IL-27Ralpha Reference Antibody (Synthekine patent anti-IL-27Ralpha) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.



The purity of Anti-IL-27Ralpha Reference Antibody (Synthekine patent anti-IL-27Ralpha) is 100%, determined by SEC-HPLC.



Immobilized Hu-IL-27Ra-ECD-His at 2 μg/mL can bind Synthekine patent anti-IL-27Ralpha, EC50= 0.006737 μg/mL.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.